What is Tevimbra?

Tevimbra is an immunotherapy infusion drug used to treat certain advanced or metastatic cancers, including esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction adenocarcinoma. It works by blocking the PD-1 protein on immune cells, helping your body attack cancer cells more effectively.

How is it given?

  • Administered via IV infusion every 3 weeks.
  • First dose takes 60 minutes; later doses may be shortened to 30 minutes if tolerated.

Before starting Tevimbra, tell your doctor if you:

  • Have autoimmune diseases (e.g., lupus, Crohn’s) or a history of organ transplants.
  • Are pregnant/planning pregnancy (requires contraception during and for 4 months post-treatment).
  • Are breastfeeding (avoid during and for 4 months after treatment).

Possible side effects:

Common reactions include fatigue, rash, or digestive issues. Serious but rare side effects may involve:

  • Lung problems (trouble breathing, cough).
  • Liver issues (yellowing skin, dark urine).
  • Hormonal gland changes (unusual headaches, weight fluctuations).

During treatment:

  • Keep all medical appointments for blood tests and monitoring.
  • Inform healthcare providers you’re on Tevimbra before any procedures or new medications.

Support resources:

  • The myBeOne Support program offers nurse advocates to help with treatment access, education, and caregiver support[6]. Call 1-833-234-4363 (M–F, 8 AM–8 PM ET).

Always consult your care team with questions or concerns about your treatment plan.

Citations:

[1] https://www.drugs.com/tevimbra.html

[2] https://www.medsafe.govt.nz/consumers/cmi/t/TevimbraInj.pdf

[3] https://www.tevimbrahcp.com/resources/

[4] https://www.hca.wa.gov/assets/pebb/sebb-regence-ump-preauthreqs-medication-covered-under-medical.pdf

[5] https://www.drugs.com/pro/tevimbra.html

[6] https://www.tevimbra.com/escc/resources/

[7] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761417s000lbl.pdf

[8] https://quizlet.com/775218490/drug-information-resources-quiz-part-11-flash-cards/

[9] https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra

[10] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf